HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Drug-eluting versus bare-metal coronary stents: where are we now?

Abstract
Drug-eluting stents have dramatically reduced the risk of restenosis, but concerns of an increased risk of stent thrombosis have provided uncertainty about their use. Recent studies have continued to show improved procedural and clinical outcomes with drug-eluting stents both in the setting of acute coronary syndromes and stable coronary artery disease. Newer generation drug-eluting stents (especially everolimus-eluting stents) have been shown to be not only efficacious but also safe with reduced risk of stent thrombosis when compared with bare-metal stents, potentially changing the benchmark for stent safety from bare-metal stents to everolimus-eluting stents. While much progress is being made in the development of bioabsorbable polymer stents, nonpolymer stents and bioabsorbable stent technology, it remains to be seen whether these stents will have superior safety and efficacy outcomes compared with the already much improved rates of revascularization and stent thrombosis seen with newer generation stents (everolimus-eluting stents and resolute zotarolimus-eluting stents).
AuthorsNicholas S Amoroso, Sripal Bangalore
JournalJournal of comparative effectiveness research (J Comp Eff Res) Vol. 1 Issue 6 Pg. 501-8 (Nov 2012) ISSN: 2042-6313 [Electronic] England
PMID24236469 (Publication Type: Comparative Study, Journal Article, Review)
Chemical References
  • Drug Combinations
  • Platelet Aggregation Inhibitors
  • Polymers
Topics
  • Absorbable Implants
  • Angioplasty, Balloon, Coronary (methods)
  • Coronary Restenosis (economics, prevention & control)
  • Cost-Benefit Analysis
  • Drug Combinations
  • Drug-Eluting Stents (economics, trends)
  • Forecasting
  • Graft Occlusion, Vascular (economics, etiology)
  • Humans
  • Myocardial Infarction (economics, therapy)
  • Myocardial Revascularization (economics, methods)
  • Percutaneous Coronary Intervention (economics, methods)
  • Platelet Aggregation Inhibitors (economics, therapeutic use)
  • Polymers (therapeutic use)
  • Stents (economics, trends)
  • Thrombosis (economics, etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: